id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343090-dsjq98ks	Fragkou, Paraskevi C.	Review of trials currently testing treatment and prevention of COVID-19	2020-05-23		.txt	text/plain	2027	153	46	OBJECTIVES: We summarised all registered clinical trials examining treatment and prevention options for COVID-19. STUDY ELIGIBILITY CRITERIA: Registered clinical trials examining treatment and/or prevention options for COVID-19 were included. property to achieve at least 10-fold higher concentrations in epithelial lung fluid than in 202 serum, have led researchers to repurpose them against SARS-CoV-2 (Table 1, Table S1 observations the antifibrotic agent pirfenidone is being evaluated in at least three randomised 215 clinical trials for its efficacy in the prevention of post-COVID-19 pneumonia fibrosis (Table 216 1, Table S1 ). Among the eligible treatment studies, 310 children recruitment (i.e.< 14 years old) was reported in 7 clinical trials in total: 1 testing 311 darunavir with cobicistat (NCT04252274); 2 on human stem cells transfusion 312 (ChiCTR2000029606, ChiCTR2000030944); 1 testing hydroxycholoroquine (EudraCT 313 Phase IV and phase III treatment trials were the most commonly reported interventional study 319 types (n=40, 20% and n=35, 18% respectively) as demonstrated in Table 3 .	./cache/cord-343090-dsjq98ks.txt	./txt/cord-343090-dsjq98ks.txt